Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (October 2013)
24 slides from Anteotech's shareholder meeting presentation, Oct 31, 2013
Slide 1: Anteo Diagnostics Annual General Meeting
For personal use only Anteo Diagnostics (ASX:ADO) Annual General Meeting 31st October 2013 Welcome
Slide 2: Meeting Format
MEETING FORMAT For personal use only Introductions Formal Resolutions CEO Report Other Business Meeting Close
Slide 3: Introductions
Introductions For personal use only Anteo Diagnostics Limited Mark Bouris– Non Executive Chairman Geoff Cumming – CEO Richard Martin – Executive Director Sandra Andersen – Non Executive Director John Hurrell – Non Executive Director Grant Thornton Matthew Bell – Partner
Slide 4: Formal Resolutions
Formal Resolutions For personal use only Resolution 1: Adoption of Directors’ Remuneration Report Resolution 2: Election of Director (Mr John Hurrell) Resolution 3: Re - Election of Director (Mr Mark Bouris) Resolution 4: Issue of 3,000,000 Options (Mr John Hurrell) Resolution 5: Issue of 6,000,000
Slide 5: Resolutions – Proxy Count
RESOLUTIONS – PROXY COUNT For personal use only Description For Against Open Abstain Totals Adoption of Directors’ Resolution 1 213,920,864 13,576,457 19,868,474 1,514,450 247,365,795 Remuneration Report Election of Director( Mr John Resolution 2 Hurrell) 209,578,975 4,000,063 34,512,706 788,501 248
Slide 6: CEO Update
For personal use only CEO UPDATE
Slide 7: Mix&Go – A Universal Glue
For personal use only TM Mix&Go – A Universal “Glue” For Clinical Diagnostics, Life Sciences and Beyond Investor Presentation October 2013 Dr. Geoff Cumming, CEO Anteo Diagnostics Ltd (ASX:ADO)
Slide 8: Anteo Diagnostics Overview
Anteo Diagnostics Overview For personal use only A Biotech company with highly experienced Board and Management team D evelops, manufactures and commercialises proprietary surface coatings for healthcare industry O ur Mix&GoTM is a novel “glue” with a ubiquitous array of applications Diagnostics (IV
Slide 9: Anteo – Corporate Overview
Anteo – Corporate Overview For personal use only Revenues from product sales Business Model Royalties from license agreements Paid R&D collaborations with IVD & LS companies Proprietary technology licensed to major Proven Technology Platform international healthcare companies with additional deals a
Slide 10: Recent Highlights
Recent Highlights For personal use only Commercial agreements 02/13 Partnership agreement with U.S. based One World Lab 02/13 Commenced paid feasibility study with global leader in lateral flow POC test manufacture 05/13 Sales partnership agreement with Spanish based Gennova Scientific for Europe &
Slide 11: Mix&Go – A Game Changing Technology
Mix&Go – For personal use only A Game Changing Technology
Slide 12: Mix&Go - A Game Changing Technology
Mix&Go - A Game Changing Technology For personal use only Surface coatings are crucial in many industries and serve many purposes, e.g.: • Provide adhesive properties, i.e. act like a “glue” • Confer optical properties • Add magnetic or electrical properties Mix&Go is a universal “glue” that is uniq
Slide 13: Current Focus: Diagnostics and Life Sciences
Current Focus: Diagnostics and Life Sciences For personal use only • Global IVD: $44B (2011) • Immunoassays: $8.8B • Drivers: aging population = Laboratory more tests, higher Asian Diagnostics demand, technology innovations • $8 B (2011) • $38B (2017 forecast) • Drivers: price pressure, lack of Poin
Slide 14: Mix&Go – The Secret Sauce
Mix&Go – The Secret Sauce For personal use only 3D structure is Orientation is Undamaged, Proprietary solution: damaged random oriented metal polymers Without Mix&Go With Mix&Go Consequences Characteristics Benefits Vast majority of proteins are non- Undamaged, fully functional proteins on Increased
Slide 15: The Proof Is In The Data
The Proof Is In The Data For personal use only Sensitivity Mix&Go™ Traditional Improvement IL4 0.05 pg/mL 0.2 pg/mL 4x Sensitivity improvement 4 to 50-fold! Troponin I 5 pg/mL 50 pg/mL 10x TNF-α 5 pg/mL > 250 pg/mL 50x HBcAg <10 pg/mL 150 pg/mL 15x TSH <0.001 uIU/mL 0.006 uIU/mL 6x Mix&Go™ Tradition
Slide 16: Mix&Go – Better Tests Faster!
Mix&Go – Better Tests Faster! For personal use only Mix&Go can improve all aspects of test development and manufacture so better tests can be developed faster New Test Possible Performance Is Key, for fragile proteins e.g. sensitivity, limit of detection Fast Development Increases speed to market Ea
Slide 17: Bioseparations – A Significant Market Opportunity
Bioseparations – For personal use only A Significant Market Opportunity
Slide 18: Bioseparation or How to Get a Pure Protein
Bioseparation or How to Get a Pure Protein For personal use only Bioseparation: isolating rare proteins or cells from a complex mixture without contamination, e.g. the purification of • Therapeutic antibodies/biologic drugs • Vaccines for human and veterinary use • Rare cells, e.g. stem cells or cir
Slide 19: Bioseparation – The Opportunity
Bioseparation – The Opportunity For personal use only Current Approach Paradigm Shift Chromatography: With Mix&Go magnetic separation • Time consuming can become reality • Expensive • technically superior solution • Hard to automate • economically advantageous • Capacity constraints Alternative Larg
Slide 20: Bioseparations: Why Now?
Bioseparations: Why Now? For personal use only Internal Drivers External Drivers • Proof of concept - Mix&Go • Increased importance - approaches show better Biologics/protein drugs play an performance than conventional ever more important role:7 out of methods the top 10 drugs sold in 2012 were biol
Slide 21: Additional Opportunities
Additional Opportunities Capitalise on For personal use only Diagnostics/POC Life Science Research Expand on Capitalise on Diagnostics/POC Bioseparations Life Science Research Expand on Develop Bioseparations Cleantech,Resources Drug screening Capitalise on Diagnostics/POC Life Science Research Init
Slide 22: Targets and Timeline
Targets and Timeline For personal use only • Agreement w/ top tier IVD • Agreement with top-tier • Agreement(s) w/ mid-tier IVD POC company • Agreement(s) w/ POC company • 2-3 agreements with LS companies • Deal(s) w/ LS companies • Agreement with top-tier POC company • Agreement with mid- size IVD
Slide 23: Keypoints
Keypoints For personal use only • Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond • Mix&Go is proven licensed and gaining significant traction in commercial markets • Mix&Go success means Anteo is becoming cash flow positi
Slide 24: Other Business and Question Time
For personal use only OTHER BUSINESS AND QUESTION TIME
Anteo Diagnostics — Shareholder Meeting (October 2013) on 6ix